Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912

Affiliations

• ¹ Stanford University School of Medicine, Stanford, California, United States.
• ² Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, United States.
• ³ Mayo Clinic, Rochester, Minnesota, United States.
• ⁴ Montefiore Medical Center, Bronx, New York, United States.
• ⁵ Chao Family Comprehensive Cancer Center at UC Irvine Medical Center, Orange, California, United States.
• ⁶ Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, Florida, United States.
• ⁷ Mayo Clinic, Scottsdale, Arizona, United States.
• ⁸ Mayo Clinic Arizona, Scottsdale, Arizona, United States.
• ⁹ Mayo Clinic, Phoenix, Arizona, United States.
• ¹⁰ Kaiser Permanente NCORP, Fresno, California, United States.
• ¹¹ Wilmot Cancer Institute, University of Rochester, Rochester, New York, United States.
• ¹² Washington University School of Medicine, St Louis, Missouri, United States.
• ¹³ Memorial Sloan Kettering Cancer Center, United States.
• ¹⁴ Minnesota Oncology, Burnsville, Minnesota, United States.
• ¹⁵ Aurora Health Care, Mount Pleasant, Wisconsin, United States.
• ¹⁶ National Cancer Institute, Bethesda, Maryland, United States.
• ¹⁷ Duke University, Durham, North Carolina, United States.
• ¹⁸ Dana-Farber Cancer Institute, Boston, Massachusetts, United States.